Skip to main content
P

ProciseDx

ProciseDx provides point-of-care therapeutic drug monitoring (TDM) solutions for infliximab and adalimumab, delivering lab-quality results in under five minutes. This technology enables gastroenterologists to obtain critical drug concentration information promptly, enhancing patient management for those with inflammatory bowel diseases.

San Diego, United StatesFounded 2018151K+ followers
Updated 4 months ago

Funding

$13M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.

Funding rounds are not available yet.

Founders

Product

Problem

Gastroenterologists managing patients with inflammatory bowel diseases (IBD) often face delays in obtaining therapeutic drug monitoring (TDM) results for drugs like infliximab and adalimumab, hindering timely treatment adjustments. Traditional lab-based TDM methods can take days or weeks, leading to suboptimal drug dosing and potentially impacting patient outcomes.

Solution

ProciseDx offers a point-of-care TDM solution that delivers lab-quality results for infliximab and adalimumab in under five minutes. Utilizing trFRET detection with proprietary compounds, the ProciseDx platform enables gastroenterologists to rapidly assess drug concentrations during patient visits. This immediate feedback allows for informed, same-day treatment decisions, optimizing drug dosing and potentially improving patient management for individuals with Crohn’s disease and ulcerative colitis. The system is designed to integrate into existing moderate complexity clinical lab workflows.

Target Audience

The primary target audience is gastroenterologists and clinical labs managing patients with inflammatory bowel diseases (IBD) who require timely and accurate therapeutic drug monitoring for infliximab and adalimumab.

Features

  • Rapid TDM results for infliximab and adalimumab in under 5 minutes
  • Point-of-care testing, eliminating the need for off-site lab analysis
  • trFRET detection technology for accurate and reliable drug concentration measurements
  • Designed for integration into moderate complexity clinical lab workflows
This profile is AI-generated and may contain inaccuracies.